"Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS"

drug protocol number
EGL-4104-C-1502
drug sponsor
Eagle Pharmaceuticals
drug study
Dantrolene
drug trial site
KFMC
drug status
Completed
drug phase